Method for selecting T cells with improved anti-cancer activity
Patent Information
- Application Number
- JP2023550709
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-05
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Optimizing the survival and function of adoptively transferred T cells in cancer treatment remains a challenge due to the host environment's metabolic regulation of T cells, where nutrient transport and tumor microenvironment negatively impact their anticancer activity.
Selecting T cells based on low levels of glucose transporter 1 (GLUT1) expression using GLUT1 ligands to enhance their anticancer activity, as T cells with low GLUT1 expression exhibit improved metabolic profiles for enhanced tumor burden reduction.
T cells with low GLUT1 expression demonstrate increased anticancer activity and effector function, effectively reducing tumor burden in tumor-bearing mice compared to T cells with high GLUT1 expression.
Smart Images

Figure 00000036_0000 
Figure 00000036_0001 
Figure 00000037_0000
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to the field of cell therapy for treating cancer. In particular, the present invention relates to a method for selecting T cells with improved anti-cancer activity, comprising: a) quantifying the expression level of glucose transporter 1 (GLUT1) on the cell surface of a T cell population using a GLUT1 ligand; and b) selecting T cells with a low GLUT1 expression level, wherein the T cells with a low GLUT1 expression level have improved anti-cancer activity. The present invention also relates to a T cell population with improved anti-cancer activity for use in treating cancer, the use of a GLUT1 ligand for selecting T cells with improved anti-cancer activity, and the use of GLUT1 as a biomarker for the anti-cancer therapeutic efficacy of T cells. [Background technology]
[0002] 2. Background of the Invention Great strides have been made in the development of T cell therapy for the treatment of cancer, however optimizing the survival and function of adoptively transferred T cells remains a challenge, resulting in the exploration and development of new strategies.
[0003] One important aspect influencing T cell proliferation and function is the host environment. Activation and effector functions of adoptively transferred T lymphocytes are associated with increased energetic and biosynthetic demands, and are generally guaranteed by increased nutrient influx and utilization. Indeed, TCR-stimulated upregulation of glucose and amino acid transporters at the cell surface may play a key role for optimal T cell proliferation and effector function. Importantly, however, distinct T lymphocyte subsets display distinct metabolic profiles: effector T cells are highly glycolytic and also lipogenic, whereas suppressive regulatory T cells (Tregs) display a mixed metabolism with increased levels of lipid oxidation. In this regard, it is interesting to note that under conditions where nutrient transport, such as glucose, glutamine or leucine transport, is limiting, the generation of Tregs, but not Teffs, is maintained (Macintyre et al., Cell Metab 20, 61-72 (2014); Nakaya et al. Immunity 40, 692-705 (2014); Sinclair et al., Nat Immunol 14, 500-508 (2013).
[0004] Moreover, the potential of engineered antitumor T cells to respond to tumor antigens is often negatively regulated by the tumor's metabolic environment, which is regulated by, among other things, nutrient composition, "waste" products, oxygen concentration, pH, temperature, and physical forces. Indeed, uncontrolled growth of cancer cells can directly affect the extracellular environment, and multiple studies have found that the metabolic phenotype of the tumor governs the subsequent immune response (reviewed in Mayers & Vander Heiden, Cancer research 77, 3131-3134 (2017)). Summary of the Invention
[0005] Given the complex cellular, signaling and metabolic landscape in tumor lesions, we sought to elucidate the metabolic signatures that promote optimal in vivo T cell antitumor effector function, particularly in "hostile" tumor tissues that consume high levels of nutrients and are often anaerobic. To this end, we specifically assessed the expression of nutrient transporters, e.g., using receptor binding domain (RBD) technology, and analyzed the in vivo antitumor properties of subpopulations of T cells with distinct nutrient transporter profiles.
[0006] Surprisingly, the inventors have shown that T cells expressing low levels of GLUT1 on the cell surface exhibit improved anti-cancer activity. In particular, the inventors have shown that T cells expressing low levels of GLUT-1 on the cell surface, adoptively transferred into tumor-bearing mice, were able to reduce tumor burden more than T cells expressing high levels of GLUT-1 on the cell surface.
[0007] Thus, the inventors have shown that T cells selected on the basis of low cell surface GLUT1 expression levels exhibit increased anti-cancer activity.
[0008] The present invention provides a method for selecting T cells with improved anti-cancer activity, comprising the steps of: a) quantifying glucose transporter 1 (GLUT1) expression levels on the cell surface of a T cell population using a GLUT1 ligand; b) selecting T cells with low levels of GLUT1 expression; Including, The T cells having low levels of GLUT1 expression have improved anti-cancer activity.
[0009] According to a first embodiment, the method comprises the steps of: a0) contacting a population of T cells which express GLUT1 on their cell surface or which are prone to express GLUT1 on their cell surface with a GLUT1 ligand; a1) detecting and / or quantifying binding of said GLUT1 ligand to GLUT1 on the cell surface of T cells; a2) quantifying GLUT1 expression levels on the cell surface of T cells; b) selecting T cells with low levels of GLUT1 expression; and c) optionally isolating selected T cells with low levels of GLUT1 expression; Includes.
[0010] According to a second embodiment, said T cells with low GLUT1 expression levels correspond to at most 50%, 40%, 30%, 20%, 10% or 5% of the total GLUT1+ T cell population that have the lowest GLUT1 expression levels.
[0011] According to a third embodiment, quantification of GLUT1 expression levels on the cell surface of T cells is performed by flow cytometry.
[0012] The present invention also relates to a T cell population with improved anti-cancer activity for use in the treatment of cancer, wherein said T cells are selected by the method of the present invention.
[0013] The present invention further relates to the use of glucose transporter 1 (GLUT1) ligands to select T cells with improved anti-cancer activity.
[0014] In some embodiments, the GLUT1 ligand is labeled.
[0015] In some embodiments, the GLUT1 ligand comprises a receptor binding domain (RBD) derived from a soluble portion of the envelope glycoprotein of a primate T-lymphotropic virus (PTLV), or comprises an antibody or antigen-binding fragment thereof.
[0016] In some embodiments, the GLUT1 ligand comprises a receptor binding domain (RBD) derived from a soluble portion of the envelope glycoprotein of human T-cell leukemia virus type 1 (HTLV-1), T-cell leukemia virus type 2 (HTLV-2), T-cell leukemia virus type 3 (HTLV-3), T-cell leukemia virus type 4 (HTLV-4), simian T-cell leukemia virus type 1 (STLV-1), simian T-cell leukemia virus type 2 (STLV-2), simian T-cell leukemia virus type 3 (STLV-3), or simian T-cell leukemia virus type 5 (STLV-5).
[0017] In some embodiments, the GLUT1 ligand comprises a receptor binding domain (RBD) derived from a soluble portion of the envelope glycoprotein of T-cell leukemia virus type 2 (HTLV-2).
[0018] In some embodiments, the receptor binding domain (RBD) comprises or consists of the amino acid sequence of SEQ ID NO:15.
[0019] The present invention also relates to the use of glucose transporter 1 (GLUT1) as a biomarker for the efficacy of anti-cancer therapy in T cells.
[0020] In some embodiments, the T cells are conventional CD4 + T cells, conventional CD8 + T cells, γδ T cells and double negative (DN) T cells.
[0021] In some embodiments, the T cells are chimeric antigen receptor (CAR) T cells.
[0022] In some embodiments, the cancer is a hematological cancer or a solid tumor.
[0023] Detailed Description The present invention provides a method, preferably an in vitro method, for selecting T cells with improved anti-cancer activity, comprising: a) quantifying glucose transporter 1 (GLUT1) expression levels on the cell surface of a T cell population using a GLUT1 ligand; b) Selecting T cells with low levels of GLUT1 expression Including, The T cells having low levels of GLUT1 expression have improved anti-cancer activity.
[0024] GLUT1 is a cell surface transporter of glucose, more precisely a glucose uptake transporter. As used herein, "GLUT1" refers to a glucose uptake transporter expressed by metazoans, particularly humans, and used as a receptor by viruses, particularly human T-cell leukemia virus (HTLV). In one embodiment, GLUT1 is human GLUT1 (Accession No. NP_006507.2, SEQ ID NO:1). In one embodiment, GLUT1 comprises or consists of an amino acid sequence exhibiting at least 70% sequence identity with SEQ ID NO:1, preferably at least 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or more sequence identity with SEQ ID NO:1. In one embodiment, GLUT1 comprises or consists of a fragment of SEQ ID NO:1, preferably a fragment of at least about 100 amino acids, more preferably a fragment of at least about 150, 200, 250, 300, 350, 400 or 450 amino acids.
[0025] In one embodiment, the method of the invention comprises determining, measuring or quantifying the expression level of GLUT1.
[0026] As used herein, the term "expression" may alternatively refer to transcription of the slc2a1 gene encoding GLUT1 (i.e., expression of RNA) or translation of GLUT1 (i.e., expression of protein), or the presence of GLUT1 at the surface of a cell. Methods for determining, measuring or quantifying expression levels are well known to those of skill in the art and include, but are not limited to, determining the transcriptome (in embodiments where expression relates to transcription of slc2a1 or GLUT1) or proteome (in embodiments where expression relates to translation of GLUT1) of a cell.
[0027] In one embodiment, the terms "determining", "measuring" or "quantifying" the expression level of GLUT1 are equivalent. As used herein, "quantifying the expression level of GLUT1" means quantifying GLUT1 present at the cell surface. Quantifying the expression level of GLUT1 present at the cell surface may include detecting GLUT1 at the cell surface. Methods for analyzing the presence of proteins at the cell surface are well known to those skilled in the art. In an embodiment, the determination, measurement or quantification of the expression level of GLUT1 is performed by flow cytometry or fluorescence activated cell sorting (FACS). In another embodiment, the determination, measurement or quantification of the expression level of GLUT1 is performed by a bead-based assay, e.g., a magnetic bead-based assay.
[0028] In one embodiment, determining, measuring or quantifying the expression level of GLUT1 corresponds to detecting and / or quantifying the binding of a ligand to GLUT1 present on the cell surface.
[0029] Therefore, another object of the present invention is a method for selecting T cells with improved anti-cancer activity, comprising the steps of: a0) contacting a population of T cells which express GLUT1 on their cell surface or which are prone to express GLUT1 on their cell surface with a GLUT1 ligand; a1) detecting and / or quantifying binding of said GLUT1 ligand to GLUT1 on the cell surface of T cells; a2) quantifying GLUT1 expression levels on the cell surface of T cells; b) selecting T cells with low levels of GLUT1 expression; and c) optionally isolating selected T cells with low levels of GLUT1 expression. The method includes:
[0030] The term "ligand" refers to any substance that binds to, specifically binds to, or forms a complex with another molecule. Exemplary ligands include, but are not limited to, small molecules such as proteins, polypeptides, peptides, peptidomimetic compounds, and other organic and inorganic small molecule compounds.
[0031] Preferably, the GLUT1 ligand is a molecule which interacts with GLUT1 on the cell surface and the method of the invention comprises detecting and / or quantifying a complex formed between said ligand and GLUT1.
[0032] The expression "interacts with GLUT1 at the cell surface" means that the ligand is susceptible to recognition of the GLUT1 receptor present at the cell surface. In one embodiment, the ligand that interacts with GLUT1 at the cell surface therefore forms a complex with said GLUT1 at the cell surface, and this complex may be detected by the method described herein above.
[0033] In one embodiment, the ligand binds to GLUT1. In one embodiment, the ligand specifically binds to GLUT1.
[0034] As used herein, the phrase "specifically binds" refers to the binding specificity and affinity of a molecule or a domain thereof for a particular target or epitope, or domain thereof, in the presence of a heterogeneous population of other proteins and biomolecules. Thus, in one embodiment, under designated assay conditions, a ligand according to the invention binds preferentially to its target, but does not bind in significant amounts to other components present in the test sample or subject. In one embodiment, such a ligand binds to a target of 1×10 -6 M or less (e.g., at least 0.5 × 10 -6 , 1×10 -7 , 1×10 -8 , 1×10 -9 , 1×10 -10The binding kinetics (e.g., binding affinity) of a molecule can also be evaluated by a standard assay known in the art, such as Biacore analysis.
[0035] The expression "detecting and / or quantifying the binding of a ligand, for example a GLUT1 ligand, to GLUT1" means that a complex is formed between GLUT1 and the ligand when GLUT1 is present on the cell surface. The complex can be detected when the ligand is covalently bound to a detectable label or molecule, for example, but not limited to, an antibody constant fragment (Fc) or a fluorescent compound. The complex can also be detected when the ligand is tagged with different means well known to those skilled in the art. Thus, the use of a ligand allows, on the one hand, the identification and detection of GLUT1 on the cell surface depending on the ligand used, and, on the other hand, the quantification of the complex formed.
[0036] In one embodiment, the GLUT1 ligand is labeled.
[0037] In one embodiment, the GLUT1 ligand is labeled with a fluorescent label. Examples of fluorescent labels include, but are not limited to, fluorescent organic dyes, quantum dots, and fluorescent proteins. These ligands can be useful as optical imaging probes.
[0038] Examples of fluorescent organic dyes include, but are not limited to, commercially available Alexa Fluor® dyes, fluorescein, rhodamine, or Cy® dyes (such as Cy3, Cy3.5, Cy5, Cy5.5, Cy7, and Cy7.5).
[0039] Examples of fluorescent proteins include, but are not limited to, BFP, CFP, GFP, EGFP, mCherry, tdTomato, mPlum, mStrawberry, J-Red, DS-Red, mOrange, mCitrine, Venus, Ypet, YFP, Emerald, etc. Another example of fluorescent protein is phycoerythrin. Fluorescent proteins can be fused to ligands by techniques of molecular cloning well known in the art. Alternatively, fluorescent proteins can be chemically conjugated to ligands by techniques well known in the art.
[0040] In one embodiment, the GLUT1 ligand is labeled with a peptide tag.
[0041] Examples of peptide tags include, but are not limited to, antibody crystallizable regions (Fc), enzymes (alkaline phosphatase or horseradish peroxidase), hemagglutinin tags, polyarginine tags, polyhistidine tags, Myc tags, Strep tags, S tags, HAT tags, 3xFlag tags, calmodulin-binding peptide tags, SBP tags, chitin-binding domain tags, GST tags, maltose-binding protein tags, fluorescent peptide tags, T7 tags, V5 tags, X-press tags, etc. Peptide tags can be fused to or covalently linked to the ligand by techniques of molecular cloning well known in the art.
[0042] In one embodiment, the GLUT1 ligand labeled as described herein is a fusion protein comprising a GLUT1 ligand (as described herein) fused to a detection tag, such as, for example, a fluorescent protein, such as GFP, RFP, BFP, YFP, and related proteins, or an Fc fragment. In one embodiment, the GLUT1 ligand is fused to an Fc fragment or a fluorescent protein. In one embodiment, the GLUT1 ligand labeled as described herein comprises a GLUT1 ligand (as described herein) chemically conjugated to phycoerythrin.
[0043] The amino acid sequence of SEQ ID NO: 2 is a non-limiting example of a GFP sequence. Examples of Fc fragments include, but are not limited to, rabbit Fc fragment (amino acid sequence of SEQ ID NO: 3) and mouse Fc fragment (amino acid sequence of SEQ ID NO: 4).
[0044] In one embodiment, the detection and / or quantification of binding is performed by flow cytometry or fluorescence activated cell sorting (FACS). In another embodiment, the detection and / or quantification of binding is performed by a bead-based assay, e.g., a magnetic bead-based assay.
[0045] In an embodiment of the invention, the ligand comprises a receptor binding domain derived from a soluble portion of an enveloped viral glycoprotein that interacts with GLUT1 at the cell surface. Preferably, the ligand is soluble, i.e. does not contain a transmembrane domain and is therefore not membrane anchored.
[0046] The expression "derived from a soluble part of a viral envelope glycoprotein" means that the ligand is a fragment of a viral envelope glycoprotein and can be obtained, for example, by cloning or gene synthesis. The term "glycoprotein" should be understood as meaning an envelope glycoprotein, a coat glycoprotein or a fusion glycoprotein, and the term "glycoprotein" refers to a protein comprising oligosaccharide chains covalently attached to a polypeptide side chain.
[0047] A receptor binding domain derived from a soluble portion of an enveloped virus glycoprotein may also be a non-glycosylated peptide or polypeptide, i.e., derived from the non-glycosylated form of the soluble portion of an enveloped virus glycoprotein.
[0048] In one embodiment, the virus is a retrovirus, preferably a delta retrovirus, such as a primate T-cell leukemia virus (PTLV), examples of which include human T-cell leukemia virus (HTLV) and simian T-cell leukemia virus (STLV).
[0049] Delta retroviruses encode envelope glycoproteins present in mature retroviral virions. The term "envelope protein" ("Env" encoded by the env gene) refers to a protein that is synthesized as a single polyprotein in the form of a propeptide and subsequently cleaved in the Golgi apparatus by furin peptidase into two components: the amino-terminal surface envelope protein ("SU protein") and the carboxy-terminal transmembrane envelope protein ("TM protein"). The Env protein is glycosylated. The SU protein is involved in binding to the host receptor. It contains a receptor binding domain (RBD) that is prone to interact with the host cell membrane receptor and a domain of interaction with the TM domain. The TM protein is located inside the lipid bilayer and anchors the SU protein to the surface of the virus particle. The TM protein mediates the membrane fusion reaction with the host cell.
[0050] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from a soluble portion of the envelope glycoprotein of a human T-cell leukemia virus.
[0051] In an embodiment, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of a human T-cell leukemia virus.
[0052] In an embodiment, the receptor binding domain is a fragment of the surface envelope protein (SU) of a human T-cell leukemia virus.
[0053] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from a soluble portion of the envelope glycoprotein of human T-cell leukemia virus type 1 (HTLV-1).
[0054] In embodiments, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of human T-cell leukemia virus type 1 (HTLV-1), preferably having an amino acid sequence comprising or consisting of SEQ ID NO:5, SEQ ID NO:32, or a fragment or variant thereof.
[0055] In embodiments, the receptor binding domain is a fragment of the surface envelope protein (SU) of human T-cell leukemia virus type 1 (HTLV-1), preferably having an amino acid sequence comprising or consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:33, SEQ ID NO:34, or a fragment or variant thereof.
[0056] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from the soluble portion of the envelope glycoprotein of the human T-cell leukemia virus type 2 (HTLV-2).
[0057] In embodiments, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of human T-cell leukemia virus type 2 (HTLV-2), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 13, SEQ ID NO: 35, or a fragment or variant thereof.
[0058] In embodiments, the receptor binding domain is a fragment of the surface envelope protein (SU) of human T-cell leukemia virus type 2 (HTLV-2), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 36 or SEQ ID NO: 37, or a fragment or variant thereof.
[0059] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from a soluble portion of the envelope glycoprotein of human T-cell leukemia virus type 3 (HTLV-3).
[0060] In embodiments, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of human T-cell leukemia virus type 3 (HTLV-3), and preferably has an amino acid sequence comprising or consisting of SEQ ID NO: 17, SEQ ID NO: 38, or a fragment or variant thereof.
[0061] In an embodiment, the receptor binding domain is a fragment of the surface envelope protein (SU) of human T-cell leukemia virus type 3 (HTLV-3), and preferably comprises or has the amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 39, or a fragment or variant thereof.
[0062] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from the soluble portion of the envelope glycoprotein of human T-cell leukemia virus type 4 (HTLV-4).
[0063] In an embodiment, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of human T-cell leukemia virus type 4 (HTLV-4), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 19, SEQ ID NO: 40, or a fragment or variant thereof.
[0064] In an embodiment, the receptor binding domain is a fragment of the surface envelope protein (SU) of human T-cell leukemia virus type 4 (HTLV-4), preferably having an amino acid sequence comprising or consisting of SEQ ID NO:20 or SEQ ID NO:21, SEQ ID NO:41, SEQ ID NO:42, or a fragment or variant thereof.
[0065] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from a soluble portion of the envelope glycoprotein of simian T-cell leukemia virus type 1 (STLV-1).
[0066] In embodiments, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of Simian T-cell Leukemia Virus Type 1 (STLV-1), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 22, SEQ ID NO: 43, or a fragment or variant thereof.
[0067] In an embodiment, the receptor binding domain is a fragment of the surface envelope protein (SU) of simian T-cell leukemia virus type 1 (STLV-1), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 23, SEQ ID NO: 44, or a fragment or variant thereof.
[0068] In an embodiment, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from a soluble portion of the envelope glycoprotein of simian T-cell leukemia virus type 2 (STLV-2).
[0069] In embodiments, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of Simian T-cell Leukemia Virus Type 2 (STLV-2), and preferably has a sequence comprising or consisting of the amino acid sequence of SEQ ID NO: 24, SEQ ID NO: 45, or a fragment or variant thereof.
[0070] In an embodiment, the receptor binding domain is a fragment of the surface envelope protein (SU) of simian T-cell leukemia virus type 2 (STLV-2), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 25, SEQ ID NO: 46, or a fragment or variant thereof.
[0071] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from a soluble portion of the envelope glycoprotein of simian T-cell leukemia virus type 3 (STLV-3).
[0072] In embodiments, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of Simian T-cell Leukemia Virus Type 3 (STLV-3), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 26, SEQ ID NO: 47, or a fragment or variant thereof.
[0073] In an embodiment, the receptor binding domain is a fragment of the surface envelope protein (SU) of simian T-cell leukemia virus type 3 (STLV-3), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 27, SEQ ID NO: 48, or a fragment or variant thereof.
[0074] In embodiments, the receptor binding domain contained in the GLUT1 ligand is isolated from or derived from a soluble portion of the envelope glycoprotein of simian T-cell leukemia virus type 5 (STLV-5).
[0075] In embodiments, the receptor binding domain comprises or consists of the entire surface envelope protein (SU) of Simian T-cell Leukemia Virus Type 5 (STLV-5), preferably having an amino acid sequence comprising or consisting of SEQ ID NO: 28, SEQ ID NO: 49, or a fragment or variant thereof.
[0076] In embodiments, the receptor binding domain is a fragment of the surface envelope protein (SU) of simian T-cell leukemia virus type 3 (STLV-3).
[0077] Preferably, the receptor binding domain is isolated from or derived from a soluble portion of the envelope glycoprotein of the T-cell leukemia virus type 2 (HTLV-2) and has a sequence that comprises or consists of the amino acid sequence of SEQ ID NO:15, referred to herein as HTLV2.RBD or H2.RBD.
[0078] The receptor binding domain contained in a GLUT1 ligand may consist of the entire RBD or a fragment or variant thereof.
[0079] A "fragment" of a reference sequence herein means a sequence that is constituted by a chain of consecutive amino acids of the reference sequence and is smaller in size than the reference sequence. In the context of the present invention, a fragment has a size of, for example, 6-200, 6-185, 6-175, 6-150, 6-125, 6-100, 6-75, 6-50, 6-25, 6-15, 6-10 amino acids, or a size of 6-185, 10-185, 25-185, 50-185, 75-185, 100-185, 125-185, 150-185, 175-185 amino acids.
[0080] As used herein, the term "variant" has the same meaning as "homologue" or "derivative." A "variant" is defined as including a sequence that is at least 75%, preferably at least 80%, preferably at least 85%, more preferably at least 90%, and even at least 95%, 96%, 97%, 98% or 99% identical to a reference sequence.
[0081] As used herein, "an amino acid sequence having at least 80% identity to a reference sequence (for example)" refers to a sequence identical to the reference sequence, but which may contain up to 20 mutations (substitutions, deletions and / or insertions) per 100 amino acid portion of the reference sequence. Thus, for a 100 amino acid reference sequence, an 80 amino acid fragment and a 100 amino acid sequence containing 20 substitutions compared to the reference sequence are two examples of a sequence having 80% sequence identity to the reference sequence.
[0082] The percentage of identity is generally determined using sequence analysis software (e.g., the Genetics Computer Group's Sequence Analysis Software Package, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). The amino acid sequences to be compared are aligned so as to obtain the maximum percentage identity. For this purpose, it may be necessary to artificially add gaps to the sequence. The alignment can be performed manually or automatically. Automatic alignment algorithms for nucleotide sequences are well known to those skilled in the art and are described, for example, in Altschul et al. (1997) Nucleic Acids Res. 25:3389 and implemented by software such as Blast software. One algorithm that can be separated is, for example, the Needleman-Wunsch algorithm (Needleman and Wunsch (1970) J Mol Biol. 48:443-53). Once optimal alignment has been achieved, the percentage identity is established by recording all positions where the amino acids of the two compared sequences are identical, relative to the total number of positions.
[0083] These variant sequences may differ from the reference sequences by one or more amino acid substitutions, deletions and / or insertions at positions such that these modifications do not have any significant effect on the biological activity of the polypeptide. Substitutions may in particular correspond to conservative substitutions or to the substitution of natural amino acids by non-natural or pseudo-amino acids.
[0084] In one particular embodiment, the sequence of the polypeptide differs from the reference sequence only by the presence of conservative substitutions. Conservative substitutions are substitutions of amino acids of the same class, such as with amino acids having uncharged side chains (such as asparagine, glutamine, serine, cysteine, and tyrosine), with amino acids having basic side chains (such as lysine, arginine, and histidine), with amino acids having acidic side chains (such as aspartic acid and glutamic acid), with amino acids having non-polar side chains (such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan).
[0085] As used herein, a "variant" of a reference protein exhibits the same biological activity as the reference polypeptide. In particular, a variant of a receptor binding domain is capable of binding to the same receptor, and a variant of a GLUT1 ligand is capable of binding to GLUT1.
[0086] When it is desired to change the amino acid sequence of a polypeptide to create an equivalent variant or part of the ligand of the present invention, or even an improved variant or part, a person skilled in the art will typically change one or more codons of the encoding DNA sequence. For example, certain amino acids can be substituted by other amino acids in the protein structure without appreciably losing the ability to bind to cell surface nutrient transporters. Since it is the binding ability and properties of a protein that define its biological functional activity, certain amino acid sequence substitutions can be made in the protein sequence, and of course in the DNA coding sequence that underlies it, to obtain a protein with similar properties. Therefore, it is contemplated that various changes can be made in the peptide sequence or the corresponding DNA sequence that encodes said peptide, without appreciably losing their biological usefulness or activity.
[0087] In preferred embodiments, the variant polypeptide differs from the reference sequence by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, deletions or additions.
[0088] In one embodiment, the receptor binding domain can be fused to an antibody constant fragment (such as a rabbit, mouse, human, monkey or other mammalian Fc fragment) and / or chemically modified to attach a fluorescent dye or compound (such as a cyanine dye, Alexa dye, Quantum dye, etc.).
[0089] In one embodiment, the GLUT1 ligand comprises a receptor binding domain, or a fragment or variant of said receptor binding domain, fused to a detection tag or label, such as, for example, an Fc fragment or GFP. An example of a GFP protein includes, but is not limited to, the amino acid sequence of SEQ ID NO: 2. An example of an Fc fragment includes, but is not limited to, a rabbit Fc fragment (such as, for example, the amino acid sequence of SEQ ID NO: 3), a mouse Fc fragment (such as, for example, the amino acid sequence of SEQ ID NO: 4), a human Fc fragment, or a monkey Fc fragment.
[0090] In some embodiments, the receptor binding domain is fused to a detection tag or label via a linker. Such linkers may be useful to prevent steric hindrance. In some embodiments, the linker has 4;5;6;7;8;9;10;11;12;13;14;15;16;17;18;19;20;21;22;23;24;25;26;27;28;29;30 amino acid residues. The linker sequence may be naturally occurring or non-naturally occurring. One useful group of linker sequences are linkers derived from the hinge region of heavy chain antibodies. Another example is a polyalanine linker sequence. Further preferred examples of linker sequences are Gly / Ser linkers of different lengths, i.e., linkers consisting of one or more glycine(s) followed by one or more serine(s).
[0091] In an embodiment, the receptor binding domain contained in the GLUT1 ligand is HTLV2.RBD fused to GFP, for example, via a Gly / Ser linker (amino acid sequence of SEQ ID NO:29 or SEQ ID NO:50). In an embodiment, the receptor binding domain contained in the GLUT1 ligand is HTLV2.RBD fused to a rabbit Fc fragment, for example, via a Gly / Ser linker (amino acid sequence of SEQ ID NO:30 or SEQ ID NO:51). In an embodiment, the receptor binding domain contained in the GLUT1 ligand is HTLV2.RBD fused to a mouse Fc fragment, for example, via a Gly / Ser linker (amino acid sequence of SEQ ID NO:31 or SEQ ID NO:52).
[0092] In an embodiment, the receptor binding domain included in the GLUT1 ligand is HTLV2.RBD fused to a human Fc fragment, for example via a Gly / Ser linker.
[0093] In another embodiment, the ligand is an antibody or an antigen-binding fragment thereof. In particular, the ligand is an antigen-binding fragment specific for GLUT1, and the method of the invention comprises detecting and / or quantifying a complex formed between the antigen-binding fragment and GLUT1.
[0094] The term "antigen-binding fragment" as used herein refers to a fragment of an antibody that has the ability to specifically interact (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution) with an epitope of an antigen. An antigen-binding fragment may in particular comprise a portion of an intact antibody, preferably the antigen-binding or variable region of an intact antibody. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments of an antibody, scFv antibody fragments, disulfide-linked Fvs (sdFv), Fd fragments consisting of VH and CHI domains, linear antibodies, single domain antibodies (either VL or VH) such as sdAb, camelid VHH domains, multispecific antibodies formed from antibody fragments such as bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDR or other epitope-binding fragments. Antigen-binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv. Antigen-binding fragments can also be grafted onto polypeptide-based scaffolds such as fibronectin type III. Papain digestion of an antibody produces two identical antigen-binding fragments called "Fab" fragments, and a remaining "Fc" fragment, named to reflect its ability to crystallize easily. The Fab fragment consists of the entire L chain together with the variable region domain (VH) of the H chain and the first constant domain (CH1) of one heavy chain. Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')2 fragment that roughly corresponds to two disulfide-linked Fab fragments with bivalent antigen-binding activity and is still capable of cross-linking antigen. The Fab' fragment differs from the Fab fragment in that it has several additional residues at the carboxy terminus of the CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
[0095] In an embodiment, said ligand is an antibody. In particular, said ligand is an antibody specific for GLUT1, and the method of the invention comprises detecting and / or quantifying a complex formed between said antibody and GLUT1.
[0096] Antibodies specific to GLUT1 are well known in the art.Preferably, the antibody does not require permeabilization to bind to GLUT1.Non-limiting examples of antibodies specific to GLUT1 include, for example, recombinant anti-glucose transporter GLUT1 antibody clone # EPR3915 available from Abcam under reference ab209449, or monoclonal mouse IgG2B clone # 202915 available from R&D Systems under reference MAB1418.
[0097] In addition to determining, measuring or quantifying the expression level of GLUT1 on the cell surface of T cells, the method of the present invention further comprises the step of selecting T cells that have a low expression level of GLUT1.
[0098] The terms "positive," "negative," "low," and "high" are well known in the art when referring to expression levels of cell surface markers.
[0099] The terms "expression," "positive," or "+" and "no expression," "negative," or "-" are well known in the art and refer to the expression level of a cellular marker of interest, where the expression level of a cellular marker corresponding to "+" is high, intermediate, or low (i.e., the cellular marker is expressed or present on the cell surface) and the expression level of a cellular marker corresponding to "-" is zero (i.e., the cellular marker is not expressed or present on the cell surface).
[0100] The terms "low" or "lo" or "lo / -" are well known in the art and refer to the expression level of a cell marker of interest in that the expression level of the cell marker is low compared to the expression level of that cell marker in the entire population of cells analyzed as a whole. More specifically, the term "lo" refers to a discrete cell population that expresses a cell marker at a lower level than one or more other discrete cell populations.
[0101] The terms "high" or "hi" or "bright" are well known in the art and refer to the expression level of a cell marker of interest in that the expression level of the cell marker is high compared to the expression level of that cell marker in the entire population of cells analyzed as a whole. More specifically, the term "hi" refers to a distinct cell population that expresses a cell marker at a higher level than one or more other distinct cell populations.
[0102] As a non-limiting example, cells with the top 2, 3, 4, 5, 10 or 15% of staining intensity are designated "hi," with the remaining cells falling into the top half of the population classified as "intermediate." Also as a non-limiting example, "positive" (or "+") cells with less than 50% of the fluorescence intensity are designated "lo" cells.
[0103] In some embodiments, determining, measuring or quantitating the expression level of GLUT1 is performed by flow cytometry or fluorescence activated cell sorting (FACS).
[0104] In some embodiments, determining, measuring or quantifying the expression level of GLUT1 comprises determining the percentage or fraction of cells from a cell population that express GLUT1 (i.e., cells "+" for GLUT1), preferably by FACS.
[0105] The expression level of GLUT1 is determined by comparing the fluorescence intensity (FI) of cells from a cell population stained with a fluorescent ligand specific for GLUT1 to the FI of cells from the same unstained cell population, or to the FI of cells from a cell population stained with a fluorescent antibody of irrelevant specificity but of the same isotype, the same fluorescent probe and from the same species (referred to as an isotype control), or to the fluorescence intensity (FI) of cells from a cell population stained with a fluorescent ligand of irrelevant specificity but of the same fluorescent probe (referred to as a control ligand), e.g., a ligand specific for a receptor not present on the cell surface of the population. Cells stained with a fluorescent antibody specific for GLUT1 and exhibiting an FI equivalent to or lower than unstained cells, or cells stained with an isotype control or control ligand, are considered not to express this marker and are designated "-" or "negative". Cells stained with a fluorescent antibody specific for GLUT1 that exhibit FI values superior to cells stained with an isotype control are considered to express GLUT1 and are designated "+" or "positive".
[0106] In some embodiments, the methods of the invention comprise determining the percentage or fraction of cells from the cell population that express lower levels of GLUT1. In a preferred embodiment, determining the percentage or fraction of cells from the cell population that express lower levels of GLUT1 is performed by flow cytometry (FACS).
[0107] In some embodiments, the methods of the present invention include selecting T cells with low GLUT1 expression levels simultaneously with or after quantifying the expression level of GLUT1 levels on the cell surface of T cells. In some embodiments, selecting T cells with low GLUT1 expression levels is performed by flow cytometry (FACS).
[0108] In embodiments, the selected T cells or T cell populations having low GLUT1 expression levels correspond to up to a 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, or 5% fraction of the lowest GLUT1 expression levels of the total GLUT1+ T cell population.
[0109] In another embodiment, the T cells or T cell subpopulation with low GLUT1 expression levels (the T cell subpopulation selected or to be selected) corresponds to the 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10% or 5% fraction with the lowest GLUT1 expression level among the total GLUT1+ T cell population.
[0110] In one embodiment, when the selection of T cells with low GLUT1 expression levels is performed by FACS, the T cells with low GLUT1 expression levels (which are selected or to be selected) are identified as the cells with the lowest 15% GLUT1 staining within the total GLUT1+ cell population.
[0111] Preferably, a T cell or T cell population with low GLUT1 expression levels has improved anti-cancer activity compared to the total T cell population, or to T cells with high GLUT1 expression.
[0112] According to certain embodiments, GLUT1 levels measured on the cell surface of T cells in the total population are divided into equal sized groups by cut-off values called "quantiles", each group corresponding to a determined percentage of T cells in the total population. Examples of quantiles include, but are not limited to, median (defining two groups based on GLUT1 levels, each containing 50% of the T cells in the total population), terciles or tertiles (defining three groups based on GLUT1 levels, each containing one third of the T cells in the total population), quartiles (defining four groups based on GLUT1 levels, each containing 25% of the T cells in the total population), quintiles (defining five groups based on GLUT1 levels, each containing 20% of the T cells in the total population) and deciles (defining ten groups based on GLUT1 levels, each containing 10% of the T cells in the total population).
[0113] "Quantile" sometimes refers to a cutoff GLUT1 value below or above which a determined percentage of T cells in the total population falls based on GLUT1 levels. Thus, subjects whose measured GLUT1 levels are below the first quantile are those with the lowest GLUT1 levels, and subjects whose measured GLUT1 levels are above the last quantile are human subjects with the highest GLUT1 levels.
[0114] Furthermore, the term "quantile" may refer to a group so defined by said cut-off value. Thus, the term "quantile" as applied to the present invention may also refer to a group of T cells defined by a cut-off GLUT1 value. For example, the first decile may refer to a group of T cells corresponding to the lowest 10% of GLUT1 levels measured in the total population. Thus, a GLUT1 value in the first decile is a GLUT1 value that is included in the lowest 10% of GLUT1 levels measured in the T cell population.
[0115] The term "quantile" as used herein preferably refers to a group so defined by said cut-off value.
[0116] In embodiments, the predetermined GLUT1 value is the first quartile of GLUT1, also referred to as GLUT1 "Q1," in the total GLUT1+ T cell population.
[0117] In an embodiment, the T cells or T cell subpopulation with low GLUT1 expression levels (the T cell subpopulation that is or is to be selected) corresponds to the first quartile of GLUT1 expression in the total GLUT1+ T cell population.
[0118] In certain embodiments, the T cell or T cell subpopulation having a low level of GLUT1 expression (the T cell subpopulation being or to be selected) corresponds to a first median, tertile, quartile, quintile or decile of GLUT1 expression in the total GLUT1+ T cell population.
[0119] In one embodiment, GLUT1 levels measured at the cell surface of T cells in the total population are divided into groups corresponding to a given percentage of T cells in the total population. As noted above, the cutoff values ("quantiles") that so divide the GLUT1 levels measured in a T cell population are referred to as "percentiles."
[0120] Thus, in one embodiment, the predetermined GLUT1 value is the first GLUT1 percentile in the total T cell population.
[0121] In one embodiment, preferably after isolation of the GLUT1+ T cell subpopulation, the selection of T cells with low GLUT1 expression levels is performed using magnetic particles, e.g. beads. For example, the selection of T cells with low GLUT1 expression levels is performed by negative magnetic immunoadhesion using a ligand for GLUT1 present on the cells, and the T cells with low GLUT1 expression levels are the "unselected" cells.
[0122] The concentration of cells and surfaces (e.g., particles such as beads) can be varied for isolation of desired cell populations by positive or negative selection, in particular to deplete T cells with high GLUT1 expression by positive selection, or to recover unbound T cells with low GLUT1 expression by negative selection.
[0123] In certain embodiments, it may be desirable to significantly increase the volume in which the beads and cells are mixed (i.e., reduce the concentration of cells) to reduce cell-bead contact. Use of low cell concentrations may reduce the efficiency of capture of T cells that express GLUT1 weakly or that express low levels of GLUT1 on the cell surface.
[0124] In one embodiment, the expression levels are normalized, i.e., the expression levels correspond to the ratio between GLUT1 expression and another gene or protein expression. For example, the other gene or protein used for normalization can be another nutrient transporter, a phenotypic marker such as CD45, CD2, CD3, CD4, CD8, or an engineered receptor such as a chimeric antigen receptor or TCR.
[0125] In the present invention, two numbers, in particular two expression levels, are considered to be different if the first number is higher than the second number (e.g., the first number is about 20% higher than the second number, preferably about 30, 40, 50, 60, 70, 80, 90% or more higher than the second number) or lower than the second number (e.g., the first number is about 20% lower than the second number, preferably about 30, 40, 50, 60, 70, 80, 90% or more lower than the second number).
[0126] The cell of the present invention is a T cell. It may be a mammalian T cell, preferably a human T cell, a livestock (e.g. bovine, porcine or equine) T cell, or a pet (e.g. feline or canine) T cell.
[0127] In some embodiments, the T cells are conventional cytotoxic T cells or conventional helper T cells.
[0128] T cells are a type of lymphocyte that develop as precursor cells from the bone marrow and migrate to the thymus where they differentiate into several distinct types of T cells.
[0129] In some embodiments, cells are obtained from a subject prior to selecting a subpopulation of T cells expressing low levels of GLUT1 as described herein. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to those skilled in the art, such as Ficoll™ separation, red blood cell lysis and monocyte depletion followed by centrifugation through a PERCOLL™ gradient, counterflow centrifugal elutriation, leukapheresis, and subsequent cell surface marker-based magnetic or flow cytometric isolation. In some embodiments, cells from an individual's circulating blood are obtained by apheresis. The apheresis product typically includes lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In some embodiments, cells from an individual's circulating blood are obtained by leukapheresis.
[0130] In some embodiments, cells collected by leukapheresis may be washed to remove the plasma fraction and place the cells in an appropriate buffer or medium for subsequent processing steps. In some embodiments of the invention, the cells are washed with phosphate buffered saline (PBS). In some embodiments, the wash solution is devoid of calcium, and may be devoid of magnesium, or may be devoid of many, if not all, divalent cations. After washing, the cells are washed with, for example, Ca 2+ PBS, Mg-free 2+ The cells may be resuspended in any of a variety of biocompatible buffers, such as PBS-free, PlasmaLyte A, or other saline solutions with or without buffering agents. Alternatively, the undesirable components of the leukapheresis sample may be removed and the cells resuspended directly in media.
[0131] In another embodiment, T cells are isolated from peripheral blood lymphocytes by lysing red blood cells and depleting monocytes, for example, by centrifugation through a PERCOLL™ gradient or by counterflow centrifugal elutriation. Specific subpopulations of T cells can be further isolated by positive or negative selection techniques. For example, in some embodiments, T cells are isolated by incubation with anti-CD3 / anti-CD28 conjugated beads, such as DYNABEADS® M-450 CD3 / CD28 T, for a period of time sufficient for positive selection of the desired T cells. Subpopulations of T cells can be preferentially selected at the beginning of culture or at other times during the process by simply shortening or lengthening the time that T cells are bound to the anti-CD3 / anti-CD28 beads and / or by increasing or decreasing the ratio of beads to T cells. Additionally, subpopulations of T cells can be preferentially selected at the beginning of culture or at other desired times by increasing or decreasing the ratio of anti-CD3 and / or anti-CD28 antibodies on the beads or other surfaces. Those skilled in the art will recognize that multiple rounds of selection can also be used in the context of the present invention.
[0132] In some embodiments, it may be desirable to perform a selection procedure and use "unselected" cells in the activation and expansion process. The "unselected" cells may also be subjected to further rounds of selection. Enrichment of the T cell population by negative selection can be achieved by a combination of antibodies against surface markers unique to the negatively selected cells. One method is sorting and / or selection of cells by negative magnetic immunoadhesion or by flow cytometry using a cocktail of monoclonal antibodies against cell surface markers present on the negatively selected cells. For example, negative selection may result in the enrichment of CD4 + To enrich for cells, the monoclonal antibody cocktail typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR and CD8.
[0133] For isolation of desired cell populations by positive or negative selection, the concentration of cells and surfaces (e.g., particles such as beads) can be varied. In certain embodiments, it may be desirable to significantly reduce the volume in which the beads and cells are mixed (i.e., increase the concentration of cells) to ensure maximum contact between the cells and beads. Furthermore, using a high cell concentration allows for more efficient capture of cells that may weakly express the target antigen of interest or from samples in which a large number of tumor cells are present (i.e., leukemic blood, tumor tissue, etc.).
[0134] In some embodiments, the T cells are conventional CD4 + T cells, conventional CD8 + T cells, γδ T cells, and double negative (DN) T cells.
[0135] In certain embodiments, the T cells are, for example, naive CD4 + T cells, helper CD4 + T cells, central memory CD4 + T cells, effector memory CD4 + T cells, or effector CD4 + Conventional CD4 such as T cells + T cells.
[0136] In some embodiments, the T cells are, for example, naive CD8 + T cells, cytotoxic CD8 + T cells, central memory CD8 + T cells, effector memory CD8 + T cells, or effector CD8 + Conventional CD8 such as T cells + T cells.
[0137] In some embodiments, the T cells are DN T cells.
[0138] In some embodiments, the T cells are γδ T cells, hi some embodiments, the T cells are TEGγδ (T cells engineered to express a defined gamma delta TCR).
[0139] In some embodiments, the T cells are T cells engineered to express a defined chimeric antigen receptor (CAR) on the cell surface.
[0140] As used herein, the term "chimeric antigen receptor" (CAR) or "chimeric receptor" (CR) refers to a polypeptide or set of polypeptides, typically two in the simplest embodiment, that when present in an immune cell provides the cell with specificity for a target ligand and results in intracellular signal generation. In some embodiments, the chimeric receptor is a chimeric fusion protein comprising a set of polypeptides. In some embodiments, the set of polypeptides comprises a dimerization switch that can couple the polypeptides to each other in the presence of a dimerization molecule, e.g., can couple a ligand binding domain to an intracellular signaling domain.
[0141] In some embodiments, the "chimeric antigen receptor" (CAR) is (a) an extracellular binding domain with determined specificity; (b) optionally an extracellular hinge domain; (c) a transmembrane domain, and (d) an intracellular signaling domain comprising a T cell primary signaling domain and, optionally, a T cell costimulatory signaling domain. Includes.
[0142] As a recombinant composite membrane receptor, CARs recognize surface antigens on target cancer cells by their extracellular domains derived from antibodies and activate engineered T cells by their intracellular signaling domains derived from T cell receptors (TCRs). After interaction with tumor antigens, T cells are activated via a combination of different signaling moieties on the CAR, which may include the CD28 costimulatory domain or the costimulatory domains of the TNF receptor family, such as 4-1BB (CD137), OX40 (CD135), and ICOS, either individually or in combination.
[0143] In some embodiments, the T cells are T cells engineered to express a defined T cell receptor (TCR) on the cell surface.
[0144] In some embodiments, the T cells with improved anti-cancer activity selected by the methods of the invention are engineered T cells.
[0145] In an embodiment, the initial T cell population is an engineered T cell population and the method of selecting T cells with improved anti-cancer activity according to the invention is performed on said already engineered T cells. In this embodiment, the T cells are first engineered and subsequently subjected to the method of selecting T cells with improved anti-cancer activity according to the invention.
[0146] In another embodiment, the method of selecting T cells with improved anti-cancer activity according to the invention is first performed on a population of unengineered T cells, and the selected T cells are then engineered.
[0147] In some embodiments, the T cells are tumor infiltrating lymphocytes (TILs).
[0148] In some embodiments, the T cells are effector T cells. In certain embodiments, effector T cells are CD4 + Effector T cells. CD4 + Examples of effector T cells include Th1 cells, Th2 cells, Th9 cells, Th17 cells, Th22 cells, and CD4+ In some embodiments, effector T cells include, but are not limited to, CD8 + In one embodiment, the T cell is an effector γδ T cell. In one embodiment, the immune cell is an effector DN T cell.
[0149] The inventors surprisingly found that GLUT1 low Adoptive transfer of T cells inhibits GLUT1 high It has been shown to substantially improve tumor rejection compared with adoptive transfer of T cells.
[0150] Furthermore, we found that low tumor burden was associated with GLUT1 expression at 43 days after adoptive transfer. high GLUT1 low It was shown to be associated with a higher percentage of T cells in the T cell population.
[0151] Thus, the present inventors surprisingly found that adoptively transferred GLUT1 low T cell populations expressing GLUT1 high The results showed that T cells selected based on low GLUT1 expression levels were better able to reduce tumor burden than T cell populations or the total T cell population. Thus, T cells selected based on low GLUT1 expression levels exhibited improved anti-cancer activity and effector function.
[0152] Thus, an object of the present invention is a T cell population with improved anti-cancer activity for use in the treatment of cancer, said T cells being selected by the selection method of the present invention.
[0153] The terms "treat" or "treatment" or "alleviate" as used herein refer to therapeutic treatments, excluding prophylactic or preventative measures, aimed at delaying (attenuating) the targeted pathological condition or disorder. Those in need of treatment include those already with the disorder and those suspected of having the disorder. A subject is successfully "treated" for a targeted pathological condition or disorder if, after administration of a therapeutic amount of a cell, cell population, composition, pharmaceutical composition or medicament according to the invention, the subject shows an observable and / or measurable reduction or absence of one or more symptoms associated with a particular disease or condition, reduced morbidity and mortality, and / or improved quality of life issues. The above parameters for assessing the success of disease treatment and alleviation are easily measurable by routine procedures that are easy for a physician to use.
[0154] Another aspect of the present invention is the use of GLUT1 ligands to select T cells with improved anti-cancer activity.
[0155] Preferably, said GLUT1 ligand is as described herein.
[0156] In some embodiments, the T cells are selected based on their GLUT1 expression, e.g., as described herein. In a preferred embodiment, the selected T cells are low T cells.
[0157] A further aspect is the use of GLUT1 as a biomarker for the efficacy of anti-cancer therapy in T cells.
[0158] As used herein, the "therapeutic effectiveness" of a compound or medicament against a pathological disease, condition or disorder in a subject in need thereof may be evident, for example, when the subject shows an observable and / or measurable reduction or absence in one or more symptoms associated with a particular disease, condition or disorder, a reduction in morbidity and mortality, and / or an improvement in quality of life issues after administration of a therapeutic amount of the compound or medicament. The above parameters for assessing the success of disease treatment and improvement are easily measurable by routine procedures that are easy for physicians to use.
[0159] In particular, where the disease is cancer, the "anti-cancer therapeutic efficacy" or "anti-cancer activity" of a compound or medicament may correspond, for example, to the ability of said compound or medicament to reduce the size of a tumor or metastasis, or to prevent the growth of a tumor or the occurrence or spread of metastases.
[0160] Provided herein is a method of treating cancer in a subject in need thereof, comprising: - selecting T cells with improved anti-cancer activity by the selection method according to the invention, and administering to a subject a therapeutic amount of said T cells having improved anti-cancer activity. Also disclosed is a method comprising:
[0161] In some embodiments, the T cells are selected based on their GLUT1 expression. Preferably, the selected T cells express GLUT1 low T cells.
[0162] The term "subject" as used herein refers to a warm-blooded animal, preferably a mammal. The term "mammal" as used herein refers to any mammal, including humans, domestic and farm animals, and zoo, sport, or pet animals, such as dogs, cats, cows, horses, sheep, pigs, goats, and rabbits. Preferably, the mammal is a primate, more preferably a human. In one embodiment, the subject may be a "patient", i.e., a subject waiting to receive medical care, or receiving medical care, or a subject that has been / is / will be the subject of a medical procedure, or a subject being monitored for the development of a disease.
[0163] In some embodiments, the T cells are autologous cells. In some embodiments, the T cells are xenogeneic cells. In some embodiments, the T cells are allogeneic cells.
[0164] A further aspect is the use of a T cell or population of T cells of the invention for the manufacture of a medicament for treating cancer.
[0165] Another aspect is a composition, pharmaceutical composition or medicament comprising a T cell or T cell population of the invention for use in the treatment of cancer.
[0166] The term "cancer" as used herein has its general meaning in the art and specifically refers to diseases caused by the uncontrolled division of abnormal cells. The term "cancer" encompasses solid tumors and hematological cancers, and includes both primary and metastatic cancers.
[0167] Examples of cancer include, but are not limited to, cancer cells of the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, digestive tract, gums, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testicles, tongue, or uterus.
[0168] In one embodiment, the cancer is a tumor, e.g., a solid tumor.
[0169] In another embodiment, the cancer is a hematological cancer. In another aspect, the cancer is a hematological malignancy. Examples of hematological cancers include, but are not limited to, Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma), and hematological cancers such as acute or chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, and myelodysplastic syndromes.
[0170] Examples of cancer include acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adenoid cystic carcinoma, adrenocortical carcinoma, AIDS-related cancer, anal cancer, appendix cancer, astrocytoma, atypical teratoma / rhabdoid tumor, B-cell leukemia, lymphoma or other B-cell malignancies, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, osteosarcoma and malignant fibrous histiocytoma, brain stem glioma, brain tumor, breast cancer, bronchial tumor, Burkitt's lymphoma, carcinoid tumor, central nervous system cancer, cervical cancer, chordoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myeloproliferative disorder, colon cancer, Cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, germinoma, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing's sarcoma family tumors, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, eye cancer, fibrous histiocytoma and osteosarcoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors (GIST), soft tissue sarcomas, germ cell tumors, gestational trophoblastic tumors, glioma, hairy cell leukemia, head and neck cancer, cardiac cancer, hepatocellular (liver) cancer, histiocytosis, Hodgkin's lymphoma, hypopharyngeal cancer, Intraocular melanoma, Insulin cell tumor (endocrine pancreas), Kaposi's sarcoma, Kidney cancer, Langerhans cell histiocytosis, Laryngeal cancer, Leukemia, Lip and oral cavity cancer, Liver cancer (primary), Lobular carcinoma in situ (LCIS), Lung cancer, Lymphoma, Macroglobulinemia, Male breast cancer, Malignant fibrous histiocytoma of bone, Medulloblastoma, Melanoma, Merkel cell carcinoma, Mesothelioma, Metastatic squamous cell neck cancer with occult primary midline carcinoma involving the NUT gene, Oral cancer, Multiple endocrine neoplasia syndrome, Multiple myeloma / plasma cell neoplasm, Mycosis fungoides, Myelodysplastic syndrome, Myelodysplastic / myeloproliferative neoplasm, Myeloid leukemia , chronic myeloid leukemia (CML), acute myeloid leukemia (AML), multiple myeloma, myeloproliferative disorders, nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, oral cancer, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillomatosis, paraganglioma, paranasal sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, intermediately differentiated pineal parenchymal tumor, pineoblastoma and supratentorial primitive neuroectodermal tumor, pituitary tumor, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma and breast cancer, primary central nervous system (CNS) lymphoma, prostate cancer,These include, but are not limited to, rectal cancer, renal cell (kidney) cancer, renal pelvis and ureter, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Sezary syndrome, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, cervical squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumor, T-cell lymphoma, skin cancer, testicular cancer, pharyngeal cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, trophoblastic tumor, ureter and renal pelvis cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, and Wilms' tumor.
[0171] In some embodiments, the cancer is a B-cell malignancy. Examples of B-cell malignancies include, but are not limited to, non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), small lymphocytic lymphoma (SLL / CLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), extranodal (e.g., MALT) lymphoma, nodal (e.g., monocytoid B-cell) lymphoma, splenic lymphoma, diffuse large cell lymphoma, B-cell chronic lymphocytic leukemia / lymphoma, Burkitt's lymphoma, and lymphoblastic lymphoma.
[0172] "Cancer" may be associated with a surface antigen, such as a cancer / tumor antigen, or a cancer / tumor marker.
[0173] The term "cancer antigen" as used herein is equivalent to "tumor antigen" and refers to an antigen that is differentially expressed by cancer cells and can therefore be utilized to target cancer cells. Cancer antigens are antigens that can potentially stimulate apparently tumor-specific immune responses. Some of these antigens are encoded by normal cells, although not necessarily expressed. These antigens can be characterized as antigens that are normally silent (i.e., not expressed) in normal cells, antigens that are expressed only at certain stages of differentiation, and transiently expressed antigens, such as embryonic and fetal antigens. Other cancer antigens are encoded by mutated cellular genes, such as oncogenes (e.g., activated ras oncogene), suppressor genes (e.g., mutant p53), and fusion proteins resulting from internal deletions or chromosomal translocations. Still other cancer antigens can be encoded by viral genes, such as those carried by RNA and DNA tumor viruses. Many tumor antigens have been defined for multiple solid tumors: MAGE1, 2, &3 (immune-defined), MART-1 / Melan-A, gp100, carcinoembryonic antigen (CEA), HER2, mucins (i.e., MUC-1), prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP). In addition, viral proteins such as those encoded by Hepatitis B (HBV), Epstein-Barr (EBV), and Human Papillomavirus (HPV) have been shown to be important in the development of hepatocellular carcinoma, lymphoma, and cervical cancer, respectively.
[0174] Other cancer antigens include 707-AP (707 alanine proline), AFP (alpha(a)-fetoprotein), ART-4 (adenocarcinoma antigen recognized by T4 cells), BAGE (B antigen; b-catenin / m, b-catenin / mutated), BCMA (B cell maturation antigen), Bcr-abl (breakpoint cluster region-Abelson), CAIX (carbonic anhydrase IX), CD19 (CD19), and CD20 (CD20). , CD22 (CD category 22), CD30 (CD category 30), CD33 (CD category 33), CD44v7 / 8 (CD category 44, exon 7 / 8), CAMEL (antigen recognized by CTLs for melanoma), CAP-1 (carcinoembryonic antigen peptide-1), CASP-8 (caspase-8), CDC27m (cell division cycle 27 mutant), CDK4 / m (cyclin-dependent kinase 4 mutant), CEA (carcinoembryonic antigen), CT (cancer / testicular ( Antigen), Cyp-B (Cyclophilin B), DAM (Differentiation antigen melanoma), EGFR (Epidermal growth factor receptor), EGFRvIII (Epidermal growth factor receptor, variant III), EGP-2 (Epithelial glycoprotein 2), EGP-40 (Epithelial glycoprotein 40), Erbb2, 3, 4 (Erythroblastic leukemia viral oncogene homolog-2, -3, 4), ELF2M (Elongation factor 2 mutant), ETV6-AML1 (Ets variant leukemia gene 6 / acute myeloid leukemia 1 gene ETS), FBP (folate binding protein), fAchR (fetal acetylcholine receptor), G250 (glycoprotein 250), GAGE (G antigen), GD2 (disialoganglioside 2), GD3 (disialoganglioside 3), GnT-V (N-acetylglucosaminyltransferase V), Gp100 (glycoprotein 100 kD), HAGE (helicose antigenantigen), HER-2 / neu (human epidermal receptor-2 / neuronal; also known as EGFR2), HLA-A (human leukocyte antigen-A) HPV (human papillomavirus), HSP70-2M (heat shock protein 70-2 variant), HST-2 (human signet ring tumor-2), hTERT or hTRT (human telomerase reverse transcriptase), iCE (intestinal carboxylesterase), IL-13R-a2 (interleukin-13 receptor subunit alpha-2), KIAA0205, KDR (kinase insert domain receptor), kappa light chain, LAGE (L antigen), LDLR / FUT (low density lipid receptor / GDP-L-fucose:bD-galactosidase 2-aL fucosyltransferase), LeY (Lewis-Y antibody), L1 CAM (L1 cell adhesion molecule), MAGE (melanoma antigen), MAGE-A1 (melanoma associated antigen 1), mesothelin, mouse CMV-infected cells, MART-1 / Melan-A (melanoma antigen recognized by T cells-I / melanoma antigen A), MC1 R (melanocortin 1 receptor), yosin / m (myosin mutant), MUC1 (mucin 1), MUM-1, -2, -3 (melanoma ubiquitous mutation-1, -2, -3), NA88-A (NA cDNA clone of patient M88), NKG2D (natural killer group 2, member D) ligand, NY-BR-1 (New York breast differentiation antigen 1), NY-ESO-1 (New York esophageal squamous cell carcinoma-1), oncofetal antigen (h5T4), P15 (protein 15), p190 minor bcr-abl (190KDbcr-abl protein), Pml / RARa (promyelocytic leukemia / retinoic acid receptor a), PRAME (preferentially expressed antigen in melanoma), PSA (prostate specific antigen), PSCA (prostate stem cell antigen), PSMA (prostate specific membrane antigen), RAGE (renal antigen), RU1 or RU2 (renal ubiquitous 1 or 2), SAGE (sarcoma antigen), SART-1 or SART-3 (squamous epithelial cell rejection antigen 1 or 3), synovial sarcoma X-1, -2, -3, -4 (SSX-1, -2, -3, -4), TAA (tumor related antigen), TAG-72 (tumor associated glycoprotein 72), TEL / AML1 (translocation Ets family leukemia / acute myeloid leukemia 1), TPI / m (triosephosphate isomerase mutant), TRP-1 (tyrosinase-related protein 1, or gp75), TRP-2 (tyrosinase-related protein 2), TRP-2 / INT2 (TRP-2 / intron 2), VEGF-R2 (vascular endothelial growth factor receptor 2), or WT1 (Wilms tumor gene).
[0175] The T cell populations of the invention may be administered alone or as a pharmaceutical composition. Preferably, the pharmaceutical composition comprises a pharma- ceutically acceptable excipient.
[0176] The term "pharmaceutical acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. The excipients do not produce adverse allergic or other undesirable reactions when administered to animals, preferably humans. For human administration, preparations must meet sterility, pyrogenicity, and general safety and purity standards as required by regulatory authorities such as the FDA and EMA.
[0177] Pharmaceutically acceptable excipients that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic substances (e.g. sodium carboxymethylcellulose), polyethylene glycol, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[0178] In one embodiment, the pharmaceutical composition according to the invention comprises a pharma- ceutically acceptable vehicle for the formulation to be injectable to a subject, which may optionally be sterile water or saline, in particular isotonic sterile saline (monosodium or disodium phosphate, sodium chloride, potassium chloride, calcium chloride or magnesium chloride, etc. or mixtures of such salts), which allows the constitution of an injectable solution upon addition of saline, or a dry composition, in particular a lyophilized composition.
[0179] The T cell populations of the present invention may be administered to a subject in any suitable manner, including injection, ingestion, transfusion, infusion, or transplantation. In some embodiments, the T cell populations may be administered to a subject by parenteral administration. In certain embodiments, the T cell populations described herein may be administered to a subject subcutaneously, intradermally, intratumorally, intranodal, intramedullary, intramuscularly, intrasternally, by intravenous (iv) injection, by infusion techniques, or intraperitoneally. In certain embodiments, the T cell populations of the present invention may be administered to a subject by intradermal or subcutaneous injection. In some embodiments, the T cell populations of the present invention may be administered by iv injection. In some embodiments, the T cell populations may be injected directly into a lymph node or tumor site.
[0180] In some embodiments, the subject is (or is to be) administered with autologous cells. In some embodiments, the subject is (or is to be) administered with xenogeneic cells. In some embodiments, the subject is (or is to be) administered with allogeneic cells.
[0181] The amount and frequency of administration of the T cells will depend on factors such as the condition of the subject and the type and severity of the subject's disease, but appropriate dosages can be determined through clinical trials.
[0182] When an "effective amount" or "therapeutic amount" is indicated, the exact amount of the T cell population or composition of the present invention to be administered can be determined taking into account individual differences in the age, weight, antibody titer, and condition of the subject. Generally, pharmaceutical compositions comprising T cells as described herein contain at least 1×10 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 Or 1×10 9 Cells / kg body weight or 1×10 5 ~100×10 5 It can be stated that the T cell composition can be administered at a dosage of 10000 cells / kg body weight (including all integer values within these ranges). The T cell composition can also be administered multiple times at any of these dosages or any combination thereof. The T cells can be administered by using injection techniques commonly known in immunotherapy. The optimal dosage and treatment regimen for a particular subject can be readily determined by monitoring the subject for symptoms of disease and adjusting the treatment accordingly.
[0183] In some embodiments, a subject (e.g., a human) receives an initial administration of a T cell or population of the invention and receives one or more subsequent administrations, where the one or more subsequent administrations are administered less than 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after the previous administration.
[0184] In some embodiments, a therapeutically effective number of the T cells of the present invention are or should be administered to a subject.
[0185] In some embodiments, the number of T cells of the T cell population of the present invention administered to a subject is at least 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 or 10 9 It is a cell.
[0186] In some embodiments, the number of T cells of the T cell population of the present invention administered to a subject is about 10 2 ~about 10 9 , about 10 3 ~about 10 8 , about 10 4 ~about 10 7 , or about 10 5 ~about 10 6 It is the range of cells.
[0187] In some embodiments, the number of T cells of the T cell population of the present invention administered to a subject is about 10 2 ~about 10 9 , about 10 2 ~10 8 , about 10 2 ~10 7 , about 10 2 ~10 6 , about 10 2 ~10 5 , about 10 2 ~10 4 , or about 10 2 ~10 3 In some embodiments, the number of T cells of the T population of the present invention administered to a subject ranges from about 10 2 , about 10 3 , about 10 4 , about 10 5 , about 10 6 , about 10 7 , about 10 8 , or about 10 9 It is a cell.
[0188] In some embodiments, the number of T cells of the T cell population of the present invention administered to a subject is at least 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 or 10 9 cells / kg body weight.
[0189] In some embodiments, the number of T cells of the T cell population of the present invention administered to a subject is about 10 2 ~10 9 cells / kg body weight or 10 3 ~10 8 cells / kg body weight ranges (including all integer values within these ranges).
[0190] In some embodiments, a subject receives more than one administration of the T cell population of the invention per week, for example, 2, 3, or 4 administrations of the T cell population of the invention administered to the subject per week.
[0191] In one embodiment, the T cell populations of the invention are to be administered prior to, simultaneously with, or after another therapeutic agent.
[0192] In some embodiments, the T cells of the invention may be administered to a subject in conjunction with (e.g., before, simultaneously with, or after) any number of relevant treatment modalities, including, but not limited to, treatment with agents such as chemotherapeutic agents.
[0193] Examples of chemotherapeutic agents include platinum coordination compounds (e.g., cisplatin, carboplatin, or oxaliplatin); taxane compounds (e.g., paclitaxel or docetaxel); topoisomerase I inhibitors (e.g., irinotecan or topotecan); topoisomerase II inhibitors (e.g., etoposide or teniposide); vinca alkaloids (e.g., vinblastine, vincristine, or vinorelbine); antitumor nucleoside derivatives (e.g., 5-fluorouracil, gemcitabine, or capecitabine); alkylating agents (e.g., nitrogen mustard or nitrosoureas, cyclophosphamide, chlorambucil, carmustine, or lomustine); antitumor anthracycline derivatives (e.g., daunorubicin, doxorubicin, idarubicin, daunorubicin ... anti-HER2 antibodies (such as, for example, trastuzumab); estrogen receptor antagonists or selective estrogen receptor modulators (such as, for example, tamoxifen, toremifene, droloxifene, faslodex or raloxifene); aromatase inhibitors (such as, for example, exemestane, anastrozole, letrazole or vorozole); differentiation agents (such as retinoids, vitamin D and retinoic acid metabolism blockers [RAMBA] such as accutane); DNA methyltransferase inhibitors (such as, for example, azacytidine); kinase inhibitors (such as, for example, flaboperidol, imatinib mesylate or gefitinib); farnesyl transferase inhibitors; and HDAC inhibitors.
[0194] The T cells of the invention may be administered to a subject before, after, or simultaneously with a chemotherapeutic agent.
[0195] It is understood that the T cells, cell populations, and compositions described herein may be used in the methods of treatment described herein, may be for pharmaceutical uses as described herein, may be for use in the treatments described herein, and / or may be for use in the manufacture of a medicament for the treatments described herein.
[0196] Sequence Listing Predicted signal peptides, if present, are shown in bold in the table below. [Table 1] TIFF2024505111000002.tif239153TIFF2024505111000003.tif228153TIFF20245051110 00004.tif236153TIFF2024505111000005.tif233153TIFF2024505111000006.tif132153 [Brief description of the drawings]
[0197] [Figure 1] Figure 1: Schematic of the experimental system used to generate T cell populations distinguished based on GLUT1 expression levels. [Diagram 2] Figure 2: Evaluation of transduction efficacy of CD19-CD28 CAR (A) and CD19-4-1-BB CAR (B) constructs on day 7 in GLUT1-Lo and GLUT1-Hi subsets of CD4+ or CD8+ T cell populations monitored by flow cytometry with protein L staining. Representative data from one of four independent experiments are shown (n=4 independent donors). [Diagram 3] Figure 3: Flow cytometric assessment of CD4 and CD8 expression profiles of cells transduced with CD19-CD28 CAR or CD19-4-1-BB CAR constructs on day 7 of expansion. Percentages of CD4+ and CD8+ T cells in GLUT1-Lo and GLUT1-Hi subsets are shown. Data are representative of the results of one of four independent experiments. [Figure 4]Figure 4: Percentages of naive (T naive, CD62L+ / CD45RA+), central memory (TCM, CD62L+ / CD45RA-), effector memory (TEM, CD62L- / CD45RA-) and effector memory re-expressing CD45RA (TEMRA, CD62L- / CD45RA+) among CD4+ T cells (A) and CD8+ T cells (B) in GLUT1-Lo and GLUT1-Hi subsets on day 6 of culture. Expression data from three independent donors are shown. [Diagram 5] Figure 5: Tumor growth follow-up by bioluminescence imaging in NSG mice injected with CD19+ GL-Nalm6 leukemia cells and adoptively transferred with mock T cells, whole CAR T cells, GLUT1-Lo CAR T cells or GLUT1-Hi CAR T cells on day 3. [Figure 6] Figure 6: Tumor growth follow-up by bioluminescence imaging in NSG mice injected with CD19+ GL-Nalm6 leukemia cells and adoptively transferred with CD19-CD28 CAR T cells (A) or CD19-4-1BB CAR T cells (B) on day 3. CAR T cells were either whole or sorted GLUT1-Lo or GLUT1-Hi T cells as indicated. [Figure 7] Figure 7: Percentage of human CD3+ CAR T cells in the spleens of NSG mice injected with CD19-CAR-BB GLUT1-Lo T cells (A) or CD19-CAR-BB GLUT1-Hi T cells (B) measured by flow cytometry on day 43.
[0198] Working Example The present invention is further illustrated by the following examples.
[0199] To test the respective anti-cancer activity of GLUT1-Hi vs. GLUT1-Lo T cells in leukemia tumor-bearing NSG mice, T cells were transduced with different CAR constructs and sorted based on GLUT1 expression before injection into tumor-bearing mice (see Examples below).
[0200] Example 1: Experimental procedure for the generation of T cell subsets with low or high GLUT1 expression levels Materials and Methods Lymphocytes from healthy donors Human healthy donor peripheral blood mononuclear cells were obtained from the NIH Blood Bank, frozen in 10% FBS, and stored in liquid nitrogen.
[0201] Generation of human CD19 CAR T cells Lentiviral vectors encoding CD19 CAR co-expressing either CD28 or 4-1BB costimulatory domains were generated by transient transfection of 293T cells (Lenti-X, Takara Bio). 293T cells were transfected with plasmids encoding packaging and envelope vectors (pMDLg / pRRE, pMD.2G, pRSV-Rev, p3000) and a plasmid encoding CD19 CAR under the control of the EF1a promoter using Lipofectamine 3000 (Life Technologies). Viral supernatants were harvested from transfected cells 24 and 48 hours after transfection, and the supernatants were centrifuged at 3,000 RPM for 10 minutes to remove cell debris.
[0202] Thaw human lymphocytes, 1 x 10 6 They were activated in AIM-V medium with Dynabeads® human T-Expander CD3 / CD28 (Invitrogen) at a ratio of 1:1 per cell in the presence of IL-2 (40 IU / mL). T cells were then cultured at 2 × 10 cells / mL in lentiviral supernatant (10 ml) supplemented with 5 mL AIM-V, 100 IU / mL IL-2, and 10 μg / mL protamine sulfate. 6The cells were resuspended at 0.3 × 10 cells / mL and then centrifuged at 2,000 × g for 2 hours at 32 °C in 6-well plates. The plates were then incubated overnight at 37 °C, and the process was repeated on day 3. After the second overnight incubation, the CD3 / CD28 microbeads were removed and T cells were sorted (see below) and plated at 0.3 × 10 cells / mL in AIM-V medium supplemented with 100 IU / mL IL-2. 6 The T cells were then resuspended at 100 µL / mL. The cells were then cultured for an additional 48–72 h before use in experiments. After generation, T cells (both CAR-transduced and mock) were cultured in AIM-V medium supplemented with 5% heat-inactivated FBS, 100 U / mL penicillin, 100 U / mL streptomycin, 2 mmol / L l-glutamine, 10 mmol / L HEPES, and 100 IU / mL IL-2.
[0203] Cell sorting based on GLUT1 expression Surface GLUT1 expression was monitored by binding to the HTLV receptor binding domain (RBD) ligand (SEQ ID NO: 15) fused to eGFP (a fusion protein with sequence SEQ ID NO: 29) as previously described (Manel et al., 2003. Cell. 115(4):449-59; Kim et al., 2004. Retrovirology. 1:41) (Metafora Biosystems). For sorting of cells based on GLUT1 expression, 50 × 10 6 Cells were stained either 4 days after stimulation, i.e. immediately after the second transduction with CD19-CAR, or 2 days after stimulation, i.e. before transduction with CD19-CAR (similar results, data not shown). Negative staining was evaluated in comparison to unstained cells. Cells designated GLUT1-Lo and GLUT1-Hi were distinguished within the positively stained population (typically >85% of all T cells) regardless of CD19-CAR staining. Within the positive population, GLUT1-Lo and GLUT1-Hi cells were identified as the cells stained with the lowest and highest GLUT1 staining of 15%, respectively. Cells were sorted on a FACS Aria (BD Biosciences) and cultured for an additional 72–96 h before evaluation.
[0204] Flow cytometry analysis The following human monoclonal antibodies were used to detect cell surface proteins: CD3-APC / Cy7, CD8-BV605, CD4-APC-R700, CD4-Pacific Blue, and CD69-APC (all from BD Bioscience). Dead cells were identified using eFluor 506 fixable viability dye (Thermo Fisher Scientific). GFP-expressing leukemias were identified in the FITC channel.
[0205] Cell surface CAR expression was assessed on day 7 by either staining with conjugated CD19-Fc-PE protein or by staining with Protein L (ThermoFisher) followed by incubation with streptavidin-PE. Staining was assessed by flow cytometry performed on an LSR II Fortessa Flow Cytometer (BD Biosciences) and data were analyzed using FlowJo software.
[0206] mouse NOD-SCID-gc- / - (NSG) mice on a Bl6 background were provided by the National Cancer Institute, Frederick. The mice were housed in standard pathogen-free facilities at the National Cancer Institute, Bethesda. Animal care and experiments were performed in accordance with National Institutes of Health (NIH) guidelines.
[0207] cell line B-ALL cell lines included the GFP-luciferase stably transfected Nalm6 line (Pediatric Oncology Branch, NCI, NIH, Bethesda, MD). Nalm6 was cultured in RPMI medium supplemented with 10% heat-inactivated FBS.
[0208] In vivo tumor experiments Animal studies were performed under protocols approved by the NCI Bethesda Animal Care and Use Committee. B-ALL cell lines were injected IV into NSG mice (1 × 10 6 After 4 days, mice were injected intravenously with 2 million CAR T cells or the same number of non-transduced MOCK control T cells. Leukemic burden was assessed using the Xenogen IVIS Lumina system (Caliper Life Sciences). After intraperitoneal injection of 3 mg D-luciferin (Caliper Life Sciences), mice were imaged 4 min later with a 30 s exposure time. Luminescence images were assessed as photons / s / cm2 / sr using Living Image version 4.1 software (Caliper Life Sciences). Mice were harvested after leukemic cell expansion to harvest spleens and bone marrow for phenotyping.
[0209] result T cells were selected based on GLUT1 glucose transporter expression (Figure 1).
[0210] Example 2: GLUT1-Hi CD4 + and CD8 + T cells are GLUT1-Lo CD4 + and CD8 + They showed higher transduction efficiency than T cells. Materials and Methods T cells bearing CD19-CD28 or CD19-4-1BB CAR constructs were generated as described in Example 1. GLUT1-Lo and GLUT1-Hi cells were sorted on day 4 as described in Example 1. On day 7, transduction efficacy was assessed as a function of surface CD19-CAR expression levels monitored by protein L staining as described in Example 1 by screening gated CD4 + and CD8 + Cells were assessed by flow cytometry.
[0211] result CD4 + and CD8 + Both subsets of T cells were transduced, but CD4 + Transduction of CD8 cells + cells, and in both cases GLUT1-Hi lymphocytes were transduced at a higher frequency than GLUT1-Lo lymphocytes (Fig. 2 ).
[0212] Example 3 :GLUT1-Hi T cells showed a skewed CD4 / CD8 ratio. Materials and Methods T cells carrying CD19-CD28 or CD19-4-1BB CAR constructs were generated as described in Example 1. GLUT1-Lo and GLUT1-Hi cells were sorted on day 4 as described in Example 1. On day 7, the CD4 and CD8 expression profiles of transduced cells were assessed by flow cytometry.
[0213] result GLUT1-Hi T cells were transduced at higher levels than GLUT1-Lo T cells, but both subsets were transduced at significant levels. Interestingly, within the GLUT1-Hi subset, there was a roughly 1:3 bias in CD4 + / CD8 + T cell ratio, but this ratio approached 1:1 within the GLUT1-low subset (Fig. 3).
[0214] Example 4: The GLUT1-Hi subset contained reduced CD8 naive T cells compared with the GLUT1-Lo subset. Materials and Methods T cells carrying CD19-CD28 or CD19-4-1BB CAR constructs were generated as described in Example 1. GLUT1-Lo and GLUT1-Hi cells were sorted on day 4 as described in Example 1. On day 6, the phenotype of T lymphocytes within the GLUT1-Lo and GLUT1-Hi subsets was assessed by flow cytometry by staining with CD62L and CD45RA markers and separating naive (CD62L+ / CD45RA+), central memory (TCM, CD62L+ / CD45RA-), effector memory (EM, CD62L- / CD45RA-) and effector memory re-expressing CD45RA (TEMRA, CD62L- / CD45RA+).
[0215] result CD8 + The difference in T cell phenotype is CD4 + T cells, and the GLUT1-Lo subset was more prominent than naive CD8 + There was a significantly higher percentage of T cells and a trend towards higher effector memory and central memory CD8 lymphocytes in the GLUT1-Hi subset (Fig. 4 ).
[0216] Example 5: Potent anti-leukemic activity of T cells selected on the basis of GLUT1 expression levels Materials and Methods For NSG mice, 1 × 10 6 CD19+GL-Nalm6 leukemia cells were injected into the mice, and on day 3, 2×10 total or FACS-sorted cells based on low or high GLUT1 expression were injected into the mice, as described in Example 1. 6 CD19-BB-CAR T cells were adoptively transferred into mice. Tumor growth was followed by bioluminescence imaging as described in Example 1.
[0217] result The activity of transferred GLUT1-Lo and GLUT1-Hi T cells was monitored in tumor-bearing NSG mice. Data from NSG mice harboring luciferase-positive CD19+Nalm6 leukemia cells demonstrated substantially improved tumor rejection upon adoptive transfer of GLUT1-Lo compared to GLUT1-Hi CD19-BB-CAR T cells (Figure 5).
[0218] Example 6: Potent anti-leukemic activity of various types of T cells selected based on GLUT1 expression levels Materials and Methods 1 × 10 in NSG mice 6 CD19+GL-Nalm6 leukemia cells were injected into the mice, and on day 3, 2×10 total or FACS-sorted cells based on low or high GLUT1 expression were injected into the mice, as described in Example 1. 6 CD19-28-CAR (Figure 6A) or CD19-1-4BB-CAR (Figure 6B) T cells were adoptively transferred into mice. Tumor growth was followed by bioluminescence imaging as described in Example 1.
[0219] result These experiments were repeated for multiple T cell donors and with both CD19-28-CAR and CD19-4-1BB-CAR T cells. As shown in Figure 7, in the stress model using the minimum number of adoptively transferred T cells, all mice receiving GLUT1-Hi T cells had significant tumor burden at day 43, and mice receiving the CD19-28-CAR construct died of leukemia. Three of four mice receiving either the full "standard" CD19-28-CAR or CD19-4-1BB CAR T cells had significant leukemia burden or died of disease, whereas two of four mice in the CD19-28-CAR GLUT1-Lo group and five of six mice in the CD19-4-1BB-CAR GLUT1-Lo group had low tumor burden (Figure 6).
[0220] Example 7: Increased survival of adoptively transferred T cells selected on the basis of low GLUT1 expression levels Materials and Methods For NSG mice, 1 × 10 6 CD19+GL-Nalm6 leukemia cells were injected into the mice, and on day 3, 2×10 6 FACS-sorted CD4-1-1BB-CAR GLUT1-Lo or GLUT1-Hi T cells were adoptively transferred into mice. Tumor growth was followed by bioluminescence imaging as described in Example 1. On day 43, the percentage of human CD3+ T cells in the spleen of each mouse was measured by flow cytometry to quantify the survival of adoptively transferred T cells.
[0221] result Lower tumor burden was associated with a higher percentage of adoptively transferred T cells in the GLUT1-Lo group than in the GLUT1-Hi group at day 43 post-adoptive transfer (Figure 7).
[0222] In conclusion, GLUT1-Lo T cells adoptively transferred into tumor-bearing mice are better able to reduce tumor burden than GLUT1-Hi T cells and total T cells. Thus, T cells selected on the basis of low GLUT1 expression levels display increased anti-cancer activity and effector function.
Claims
1. 1. A method for selecting T cells with improved anti-cancer activity, comprising: a) quantifying glucose transporter 1 (GLUT1) expression levels using a GLUT1 ligand on the cell surface of a T cell population; b) selecting T cells with low levels of GLUT1 expression; Including, The T cells having low GLUT1 expression levels have improved anti-cancer activity.
2. a0) contacting a T cell population that expresses GLUT1 on their cell surface or is susceptible to express GLUT1 on their cell surface with a GLUT1 ligand; a1) detecting and / or quantifying binding of said GLUT1 ligand to GLUT1 on the cell surface of said T cells; a2) quantifying the expression level of GLUT1 on the cell surface of said T cells; and b) selecting T cells with low levels of GLUT1 expression; The method of claim 1 , comprising:
3. The method described in claim 1 or 2, further comprising: c) isolating selected T cells having a low GLUT1 expression level.
4. 4. The method of any one of claims 1 to 3, wherein the T cells with low GLUT1 expression levels correspond to at most 50%, 40%, 30%, 20%, 10% or 5% of the total GLUT1+ T cell population that have the lowest GLUT1 expression levels.
5. The method according to any one of claims 1 to 4, wherein the quantification of the GLUT1 expression level on the cell surface of the T cells is carried out by flow cytometry.
6. 6. A pharmaceutical composition comprising a population of T cells with improved anti-cancer activity for use in the treatment of cancer, wherein said T cells have been selected by the method of any one of claims 1 to 5.
7. Use of glucose transporter 1 (GLUT1) ligands to select T cells with improved anti-cancer activity.
8. The method according to any one of claims 1 to 5, the pharmaceutical composition according to claim 6, or the use according to claim 7, wherein the GLUT1 ligand is labeled.
9. 9. The method, use or pharmaceutical composition of any one of claims 1 to 8, wherein the GLUT1 ligand comprises a receptor binding domain (RBD) derived from a soluble portion of the envelope glycoprotein of the Primate T-lymphotropic Virus (PTLV) or comprises an antibody or antigen-binding fragment thereof.
10. 10. The method, use or pharmaceutical composition of claim 9, wherein the GLUT1 ligand comprises a receptor binding domain (RBD) derived from a soluble portion of the envelope glycoprotein of human T-cell leukemia virus type 1 (HTLV-1), T-cell leukemia virus type 2 (HTLV-2), T-cell leukemia virus type 3 (HTLV-3), T-cell leukemia virus type 4 (HTLV-4), simian T-cell leukemia virus type 1 (STLV-1), simian T-cell leukemia virus type 2 (STLV-2), simian T-cell leukemia virus type 3 (STLV-3), or simian T-cell leukemia virus type 5 (STLV-5).
11. 11. The method, use or pharmaceutical composition of claim 10, wherein said GLUT1 ligand comprises a receptor binding domain (RBD) derived from a soluble portion of the envelope glycoprotein of T-cell leukemia virus type 2 (HTLV-2).
12. 12. The method, use or pharmaceutical composition of claim 11 , wherein the receptor binding domain (RBD) comprises or consists of the amino acid sequence of SEQ ID NO:
15.
13. Use of glucose transporter 1 (GLUT1) as a biomarker for T cell anti-cancer therapeutic efficacy.
14. The T cells are conventional CD4 + T cells, conventional CD8 + 14. The method, use or pharmaceutical composition of any one of claims 1 to 13, wherein the T cells are selected from the group consisting of γδ T cells, γδ T cells and double negative (DN) T cells.
15. 15. The method, use or pharmaceutical composition of any one of claims 1 to 14, wherein said T cells are chimeric antigen receptor (CAR) T cells.
16. The method, use or pharmaceutical composition of any one of claims 1 to 15, wherein the cancer is a hematological cancer or a solid tumor.
